Frontline Therapy in Newly Diagnosed Advanced Hodgkin Lymphoma

There continues to be excitement among Hodgkin lymphoma specialists about the use of a new drug, Brentuximab Vedotin, with new early data suggesting it may have use as part of combination therapy in the frontline setting. Dr. Steven Park, a specialist at the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, provides analysis from the 2012 American Society of Hematology meeting on how the new combination may, one day, be “practice changing.” He also reports on new data related to limiting toxicity from radiation treatment.